Pertussis: persistent pathogen, imperfect vaccines (Q35193561)

7 August 2017

1 reference

title

Pertussis: persistent pathogen, imperfect vaccines (English)

1 reference

7 August 2017

Sylvia H Yeh

1

1 reference

7 August 2017

publication date

1 February 2003

1 reference

Expert Review of Vaccines

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

1

1 reference

7 August 2017

page(s)

113-127

1 reference

Mechanisms of Bordetella pathogenesis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Pertussis is a frequent cause of prolonged cough illness in adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Failure of physicians to consider the diagnosis of pertussis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Issues associated with and recommendations for using PCR to detect outbreaks of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Antimicrobial treatment of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.1.113

21 January 2018

Identifiers

DOI

10.1586/14760584.2.1.113

1 reference

7 August 2017

1 reference